A Phase 3 Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous to Oral 6-Day TR-701 Free Acid and Intravenous to Oral 10-Day Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Latest Information Update: 14 Dec 2023
At a glance
- Drugs Tedizolid (Primary) ; Tedizolid (Primary) ; Linezolid; Linezolid
- Indications Gram-positive infections; Methicillin-resistant Staphylococcus aureus infections; Skin and soft tissue infections
- Focus Registrational; Therapeutic Use
- Acronyms ESTABLISH-2
- Sponsors Trius Therapeutics
- 12 May 2019 This trial has been completed in Spain as per European Clinical Trials Database record.
- 01 Dec 2018 Results of post-hoc pooled subgroup analysis of ESTABLISH and ESTABLISH-2 trials (n=1333) assessing efficacy and safety published in the Infectious Diseases and Therapy.
- 06 Mar 2017 Results of subgroup analysis of pooled efficacy data from two phase III trials (ESTABLISH-1 and ESTABLISH-2) published in the Antimicrobial Agents and Chemotherapy